Basic Information
| LncRNA/CircRNA Name | circMras |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | NA | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | qRT-PCR , western blot , luciferase reporter assay , RIP , FISH , RNase R treatment , cell viability assay , transwell assay , colony formation assay |
| Sample | LUAD and healthy tissues ,human non-small cell lung carcinoma (A549, H1975 and H1299) and normal lung epidermal cell line (HBE) |
| Expression Pattern | down-regulated |
| Function Description | Thirty-six paired LUAD and healthy tissues were collected and cMras resulted significantly downregulated in cancerous tissues. Its expression was negatively associated with tumour stages. cMras overexpression suppressed LUAD growth and metastasis, while endogenous cMras silencing resulted in the opposite effects.cMras was a sponge of miRNA-567 and released its direct target, PTPRG. cMras overexpression decreased miR-567 expression and subsequently increased PTPRG expression, while increased miRNA-567 expression blocked the effects induced by cMras. Moreover, PTPRG was downregulated in LUAD and patients with low PTPRG expression exhibited significantly poor prognosis. |
| Pubmed ID | 31012177 |
| Year | 2019 |
| Title | Circular RNA cMras inhibits lung adenocarcinoma progression via modulating miR??67/PTPRG regulatory pathway |
External Links
| Links for circMras | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |